ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.

Milan Radovich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.